Flow diagram.
APPENDIX, SEVERE ACUTE RESPIRATORY SYNDROME, CORONAVIRUS
For the primary outcome, all patients were analyzed according to the intention-to-treat principle. *Twenty-four patients with initial indeterminate SARS-CoV-2 results were retested: 2 had positive results, 16 had negative results, and 6 had indeterminate results. **The “rapid multiplex test” refers to the multiplex PCR assay QIAstat-Dx respiratory SARS-CoV-2 panel. The “rapid molecular test” refers to the Abbott ID NOW COVID-19 assay, an isothermal nucleic acid amplification assay based on a NEAR technique. CI, confidence interval; ED, emergency department; NEAR, nicking and extension amplification reaction; PCR, polymerase chain reaction; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.Overall, 4,283 asymptomatic/paucisymptomatic patients were screened, including 3,682 (86.0%) patients who underwent a rapid molecular SARS-CoV-2 test, resulting in 224 (5.2%) new SARS-CoV-2 diagnoses. Among the asymptomatic/paucisymptomatic patients screened, 80.9% did not report symptoms and 41.6% reported not having been tested previously. Of the 224 newly diagnosed patients, 38.4% did not report symptoms (Appendix E in During the intervention period, 17,512 patients were screened in routine practice, resulting in 1,635 (9.3%) new SARS-CoV-2 diagnoses.In total, during this period, 1,859 patients were newly diagnosed among 69,248 patients (26.8/1,000 patients (95% CI [25.7, 28.1]) (